Zurcher Kantonalbank Zurich Cantonalbank Buys 1,162 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 9.0% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 14,126 shares of the company’s stock after acquiring an additional 1,162 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Syndax Pharmaceuticals were worth $305,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Syndax Pharmaceuticals by 11.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,897 shares of the company’s stock worth $1,013,000 after acquiring an additional 4,705 shares during the period. Arizona State Retirement System boosted its stake in Syndax Pharmaceuticals by 5.3% in the 4th quarter. Arizona State Retirement System now owns 16,511 shares of the company’s stock valued at $357,000 after purchasing an additional 835 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Syndax Pharmaceuticals by 352.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,058 shares of the company’s stock valued at $174,000 after buying an additional 6,276 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Syndax Pharmaceuticals by 5.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 411,965 shares of the company’s stock worth $8,903,000 after buying an additional 21,427 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in shares of Syndax Pharmaceuticals by 196.4% during the fourth quarter. SG Americas Securities LLC now owns 29,169 shares of the company’s stock worth $630,000 after buying an additional 19,328 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. Scotiabank lowered shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and decreased their target price for the stock from $36.00 to $23.00 in a research report on Wednesday, January 31st. JPMorgan Chase & Co. lifted their price target on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a research report on Wednesday, March 20th. Finally, HC Wainwright reissued a “buy” rating and set a $41.00 price target on shares of Syndax Pharmaceuticals in a research report on Friday, April 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.42.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock opened at $22.05 on Monday. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $11.22 and a fifty-two week high of $25.34. The stock’s fifty day moving average price is $22.56 and its two-hundred day moving average price is $19.99. The company has a market cap of $1.87 billion, a PE ratio of -7.45 and a beta of 1.01.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.01). During the same quarter last year, the business earned ($0.62) earnings per share. On average, equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.74 EPS for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).